Last reviewed · How we verify

Local steroid - triamcinolone acetonide

Instituto do Cancer do Estado de São Paulo · FDA-approved active Small molecule

Triamcinolone acetonide is a synthetic corticosteroid that suppresses local inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.

Triamcinolone acetonide is a synthetic corticosteroid that suppresses local inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Local inflammatory skin conditions (eczema, psoriasis, lichen planus), Intralesional treatment of keloids and hypertrophic scars, Intra-articular injection for inflammatory arthritis.

At a glance

Generic nameLocal steroid - triamcinolone acetonide
SponsorInstituto do Cancer do Estado de São Paulo
Drug classCorticosteroid (glucocorticoid)
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaDermatology, Rheumatology, Immunology
PhaseFDA-approved

Mechanism of action

As a potent glucocorticoid, triamcinolone acetonide reduces inflammation, immune cell infiltration, and vascular permeability at the site of administration. When applied locally (intralesional, topical, or intra-articular), it minimizes systemic exposure while delivering high local anti-inflammatory and immunosuppressive effects. It is commonly used to manage inflammatory and allergic conditions affecting skin, joints, and mucous membranes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: